VISAKHAPATNAM: The Visakha Institute of Medical Science has got approval to conduct third phase clinical trials of Covid-19 intranasal vaccine. VIMS is the only institution in the state to get an opportunity to conduct the trials. Being developed by Bharat Biotech, the first and second phase trials have already been completed.
Speaking to TOI, director, VIMS, Dr K Rambabu said this is the first of its kind Covid-19 jab to undergo human clinical trials in India. “We will conduct trials on as many as 3,160 people. While 3,000 people will receive intranasal vaccination, the remaining 160 people will be administered the intramuscular Covaxin. This is to evaluate both safety and immunogenicity,” said Dr Rambabu, who also works as the principal investigator of the trials.
